Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.70 |
| ▸ | NAT1 | P18440 | 8/20 | 0.60 |
| ▸ | MYC | P01106 | 1/20 | 0.60 |
| ▸ | MAX | P61244 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | PTP4A3 | O75365 | 2/20 | 0.58 |
| ▸ | CRHBP | P24387 | 1/20 | 0.58 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.58 |
| ▸ | INSR | P06213 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 1/20 | 0.58 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.55 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14661290 | 1.00 | PIM1 (0.70) | PIM1NAT1MYCMAXCA2 | |
| SCHEMBL14661291 | 1.00 | PIM1 (0.70) | PIM1NAT1MYCMAXCA2 | |
| SCHEMBL14660903 | 0.90 | PIM1 (0.62) | PIM1NAT1MYCMAXCA2 | |
| SCHEMBL18102853 | 0.90 | NAT1 (0.62) | PIM1NAT1MYCMAXCA2 | |
| SCHEMBL13846835 | 0.90 | PIM1 (0.62) | PIM1NAT1MYCMAXCA2 | |
| SCHEMBL1249831 | 0.83 | PIM1 (0.62) | PIM1IGF1RCISD1 | |
| SCHEMBL1249833 | 0.83 | PIM1 (0.62) | PIM1IGF1RCISD1 | |
| SCHEMBL9251192 | 0.83 | PIM1 (0.78) | PIM1NAT1MYCMAXCA2 | |
| SCHEMBL9251195 | 0.83 | PIM1 (0.78) | PIM1NAT1MYCMAXCA2 | |
| SCHEMBL12892060 | 0.83 | PIM1 (1.00) | PIM1NAT1MYCMAXCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312708-B2 | Process and intermediates for the preparation of benzo[b]thiophene compounds | CRYSTAL PHARMA, S.A.U. (ES) | 2022-04-26 | — | — | US | disclosed |
| US-20200172523-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CURIA SPAIN, S.A.U. (ES) | 2020-06-04 | — | — | US | disclosed |
| US-20190040048-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CURIA SPAIN, S.A.U. (ES) | 2019-02-07 | — | — | US | disclosed |
| EP-3150591-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | Crystal Pharma S.A.U (ES) | 2017-04-05 | — | — | EP | disclosed |
| US-8431376-B2 | Bacterial replication systems and methods | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431376-B2 | Bacterial replication systems and methods | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2541329-A1 | CHARGE CONTROLLING AGENT AND TONER USING SAME | Hodogaya Chemical Co., Ltd. (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120315576-A1 | CHARGE CONTROLLING AGENT AND TONER USING SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120315576-A1 | CHARGE CONTROLLING AGENT AND TONER USING SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20100028862-A1 | BACTERIAL REPLICATION SYSTEMS AND METHODS | Replidyne,Inc. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100028862-A1 | BACTERIAL REPLICATION SYSTEMS AND METHODS | Replidyne,Inc. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2006071255-A9 | BACTERIAL REPLICATION SYSTEMS AND METHODS | REPLIDYNE INC (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172523-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CYP4X1, CYP2B6, CYP2C19 | PIM1 1755/4885NAT1 889/4885MYC 3067/4885 |
| US-20190040048-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CYP4X1, CYP2B6, CYP2C19 | PIM1 1755/4885NAT1 889/4885MYC 3067/4885 |
| US-11312708-B2 | Process and intermediates for the preparation of benzo[b]thiophene compounds | CYP4X1, CYP2B6, CYP2C19 | PIM1 1755/4885NAT1 889/4885MYC 3067/4885 |
| US-20120315576-A1 | CHARGE CONTROLLING AGENT AND TONER USING SAME | NPY1R, HCRTR1, CCKAR | PIM1 3705/4885NAT1 1604/4885MYC 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.